Europe

Genomics England launched, DNA mapping

Wednesday, July 10, 2013 12:16 PM

Genomics England, an organization owned by DH, has launched a personal DNA code project. The personal DNA code—known as a genome—of up to 100,000 patients or infections in patients will be sequenced over the next five years.

More... »

The Royal Liverpool University Hospital achieves highest level of accreditation

Wednesday, July 3, 2013 02:20 PM

The Covance-Royal Liverpool University Hospital Clinical Research Unit (the Royal)—has become the first National Health Service (NHS) facility in England to be granted Medicines and Healthcare products Regulatory Agency (MHRA) standard and supplementary phase I accreditation.

More... »

Heptares grants Shire worldwide NDC license

Wednesday, July 3, 2013 10:00 AM

Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares Therapeutics, currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

More... »

Report: British patients participating in clinical research at highest level in six years

Tuesday, July 2, 2013 03:15 PM

A new report released by the National Institute for Health Research Clinical Research Network (the clinical research delivery arm of the NHS) shows that more than 630,000 NHS patients in England took part in clinical research studies last year—the highest level since the Network began keeping track six years ago.

More... »

Karolinska Development, Novo Seeds and Finnvera invest in Forendo Pharma

Wednesday, June 26, 2013 02:53 PM

Karolinska Development has invested in Forendo Pharma, a new drug development company based in Finland, together with Novo Seeds and Finnvera.

More... »

AmVac receives two E.U. grants for development of novel vaccines

Tuesday, June 25, 2013 09:37 AM

Biopharmaceutical AmVac has announced that the E.U. approved two grant applications under the seventh framework program (FP7) for the development of vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with expertise in vaccine design and development. Total funding for all participating partners is approximately $7.8 million and $7.2 million, respectively, over five years. Within the funding periods, both vaccines are expected to complete phase I clinical trials.

More... »

AstraZeneca selects Cambridge, U.K. for R&D center and corporate headquarters

Thursday, June 20, 2013 11:00 AM

AstraZeneca is building a new $514 million global R&D center and corporate headquarters on the Cambridge Biomedical Campus. By 2016, the new site will house 2,000 employees.

More... »

ERT announces enhancements on AVERT

Thursday, June 20, 2013 08:02 AM

ERT, a global solution provider for patient safety and efficacy endpoint data collection, has announced enhancements to AVERT, its electronic suicide risk assessment system. Having captured over 100,000 assessments to date, AVERT is a tool for biopharmaceutical developers who need to assess for suicide risk during clinical development programs.

More... »

Athera Biotechnologies awarded collaborative research grant

Monday, June 17, 2013 01:45 PM

Athera Biotechnologies said future development costs of its fully human antibody PC-mAb, until proof-of-concept, will be co-funded by the European Union’s Seventh Framework Program for Research (FP7) through a collaborative research grant.

More... »

Icon, University College Dublin launch graduate certificate in clinical research

Monday, June 17, 2013 01:43 PM

Iconand the University College Dublin (UCD) School of Medicine & Medical Science have launched a graduate certificate in clinical research.

More... »